دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Seventh Annual Go Red for Women Issue.
Al-Khatib, Sana M. MD, MHS; Hill, Joseph A. MD, PhD; Carnethon, Mercedes PhD
doi : 10.1161/CIRCULATIONAHA.123.063932
Volume 147(7) pgs. 519-619,e76-e91 February 14, 2023
Sex Disparities in Cardiology: How Are We Doing in Latin America?.
Bahit, M. Cecilia MD; Salvati, Ana MD
Sex Disparities in Prevention of Atherosclerotic Cardiovascular Disease Across the Life Course.
Rodriguez, Fatima MD, MPH
What Can Cardiologists Do to Reduce the High Risk of Maternal Mortality in the United States?.
Volgman, Annabelle Santos MD; Dye, Cicely A. MD; Sanghani, Rupa M. MD
Beyond Sex-Based Medicine in Cardiovascular Health Research and Practice.
Beach, Lauren B. PhD, JD; Streed, Carl G. Jr MD, MPH
Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study.
Foulkes, Stephen J. PhD; Howden, Erin J. PhD; Haykowsky, Mark J. PhD; Antill, Yoland MD; Salim, Agus PhD; Nightingale, Sophie S. MD; Loi, Sherene MD, PhD; Claus, Piet PhD; Janssens, Kristel BN; Mitchell, Amy M. BSc; Wright, Leah PhD; Costello, Ben T. MD, PhD; Lindqvist, Anniina BSc; Burnham, Lauren BSc; Wallace, Imogen BSc; Daly, Robin M. PhD; Fraser, Steve F. PhD; La Gerche, Andre MD, PhD
doi : 10.1161/CIRCULATIONAHA.122.062814
Breast cancer survivors treated with anthracycline-based chemotherapy (AC) have increased risk of functional limitation and cardiac dysfunction. We conducted a 12-month randomized controlled trial in 104 patients with early-stage breast cancer scheduled for AC to determine whether 12 months of exercise training (ExT) could attenuate functional disability (primary end point), improve cardiorespiratory fitness (VO2peak), and prevent cardiac dysfunction.
Does Physical Activity During Cancer Treatment Preserve Exercise Capacity?.
Bottinor, Wendy MD, MSCI; Hundley, W. Gregory MD
Maternal Outcomes Among Pregnant Women With Congenital Heart Disease-Associated Pulmonary Hypertension.
Zhang, Qian MD ,*; Zhu, Fang MD ,,*; Shi, Guocheng MD ,*; Hu, Chen MD; Zhang, Weituo PhD; Huang, Puzhen MD; Zhu, Chunfeng MD, PhD; Gu, Hong MD, PhD; Yang, Dong MD, PhD; Li, Qiangqiang MD; Niu, Yonghua MD; Chen, Hao MD; Ma, Ruixiang MD; Pan, Ziyi MD; Miao, Huixian MD; Zhang, Xin MD; Li, Genxia MD; Tang, Yabing MD; Qiao, Guyuan MD; Yan, Yichen MD; Zhu, Zhongqun MD, PhD; Zhang, Hao MD, PhD; Han, Fengzhen MD; Li, Yanna MD; Lin, Jianhua MD, PhD; Chen, Huiwen MD, PhD
doi : 10.1161/CIRCULATIONAHA.122.057987
Studies focused on pregnant women with congenital heart disease (CHD)-associated pulmonary hypertension (PH) are scarce and limited by small sample sizes and single-center design. This study sought to describe the pregnancy outcomes in women with CHD with and without PH.
Pregnancy and Congenital Heart Disease-Associated Pulmonary Hypertension: Are Outcomes Improving?.
Chin, Kelly M. MD; Santiago-Munoz, Patricia MD
Maternal Exposure to PM2.5 and the Risk of Congenital Heart Defects in 1.4 Million Births: A Nationwide Surveillance-Based Study.
Yuan, Xuelian MPH ,,*; Liang, Fengchao PhD ,,*; Zhu, Jun MS; Huang, Keyong PhD; Dai, Li PhD; Li, Xiaohong PhD; Wang, Yanping MS; Li, Qi MA; Lu, Xiangfeng PhD; Huang, Jianfeng MD; Liao, Lihui BS; Liu, Yang PhD; Gu, Dongfeng PhD; Liu, Hanmin MD ,,,,+; Liu, Fangchao PhD ,,+
doi : 10.1161/CIRCULATIONAHA.122.061245
Evidence remains limited about the association of maternal exposure to ambient fine particulate matter (airborne particles with an aerodynamic diameter <=2.5 [micro]m [PM2.5]) with fetal congenital heart defects (CHDs) in highly polluted regions, and few studies have focused on preconception exposure.
Sex Differences in 10-Year Outcomes After Percutaneous Coronary Intervention With Drug-Eluting Stents: Insights From the DECADE Cooperation.
Coughlan, J.J. MB, BCh, MD; Raber, Lorenz MD, PhD; Brugaletta, Salvatore MD, PhD; Kufner, Sebastian MD; Maeng, Michael MD, PhD; Jensen, Lisette Okkels MD, PhD; Ortega-Paz, Luis MD, PhD; Bar, Sarah MD; Laugwitz, Karl-Ludwig MD; Madsen, Morten MSc, BA; Heg, Dik PhD; Aytekin, Alp MD; Windecker, Stephan MD; Olesen, Kevin Kris Warnakula MD, PhD; Sabate, Manel MD, PhD; Kastrati, Adnan MD; Cassese, Salvatore MD, PhD
doi : 10.1161/CIRCULATIONAHA.122.062049
Although some studies have investigated sex-related outcomes up to 5 years after percutaneous coronary intervention (PCI), analyses at longer follow-up (ie, to 10 years) in large cohorts treated exclusively with drug-eluting stent (DES) platforms are lacking.
Comparative Effectiveness of Left Atrial Appendage Occlusion Versus Oral Anticoagulation by Sex.
Zeitler, Emily P. MD, MHS; Kearing, Stephen MS; Coylewright, Megan MD, MPH; Nair, Devi MD; Hsu, Jonathan C. MD, MAS; Darden, Douglas MD; O'Malley, A. James PhD; Russo, Andrea M. MD; Al-Khatib, Sana M. MD, MHS
doi : 10.1161/CIRCULATIONAHA.122.062765
The comparative real-world outcomes of older patients with atrial fibrillation (AF) treated with anticoagulation compared with left atrial appendage occlusion (LAAO) may be different from those in clinical trials because of differences in anticoagulation strategies and patient demographics, including a greater proportion of women
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?.
Cho, Leslie MD; Kaunitz, Andrew M. MD; Faubion, Stephanie S. MD, MBA; Hayes, Sharonne N. MD; Lau, Emily S. MD, MPH; Pristera, Nicole MD; Scott, Nandita MD; Shifren, Jan L. MD; Shufelt, Chrisandra L. MD, MS; Stuenkel, Cynthia A. MD; Lindley, Kathryn J. MD; for the ACC CVD in Women Committee
doi : 10.1161/CIRCULATIONAHA.122.061559
AB Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly.
Muscle Sympathetic Action Potential Firing Patterns During Normotensive and Hypertensive Pregnancy: A Longitudinal Assessment.
Badrov, Mark B. PhD; Yoo, Jeung-Ki PhD; Hissen, Sarah L. PhD; D'Souza, Andrew W. MSc; Nelson, David B. MD; Shoemaker, J. Kevin PhD; Fu, Qi MD, PhD
Randomized Controlled Trial of a Smartphone-Based Intervention to Enhance 6-Minute Walk Distance During Breast Cancer Treatment: The SMART-BREAST Trial.
Murphy, Alexandra C. MBBS, BMedSci; Farouque, Omar MBBS, PhD; Koshy, Anoop N. MBBS, PhD; Yeo, Belinda MBBS, MD; Dick, Ron MBBS; Nadurata, Voltaire MBBS; Roccisano, Laura RN; Reid, Christopher PhD; Yudi, Matias B. MBBS, PhD
Long-Term Adverse Outcomes in Black Women With Ischemia and No Obstructive Coronary Artery Disease: A Study of the WISE (Women's Ischemia Syndrome Evaluation) Cohort.
Luu, Judy M. MD, PhD ,*; Malhotra, Pankaj MD ,*; Cook-Wiens, Galen MS; Pepine, Carl J. MD; Handberg, Eileen M. PhD; Reis, Steven E. MD; Reichek, Nathaniel MD; Bittner, Vera MD; Wei, Janet MD; Kelsey, Sheryl F. PhD; Sailaja Marpuri, Reddy MS; Sopko, George MD; Bairey Merz, C. Noel MD
Optimizing Prepregnancy Cardiovascular Health to Improve Outcomes in Pregnant and Postpartum Individuals and Offspring: A Scientific Statement From the American Heart Association.
Khan, Sadiya S. MD, MSc, FAHA, Chair; Brewer, LaPrincess C. MD, MPH; Canobbio, Mary M. RN, MN, FAHA; Cipolla, Marilyn J. PhD, FAHA; Grobman, William A. MD, MBA; Lewey, Jennifer MD, MPH; Michos, Erin D. MD, MHS; Miller, Eliza C. MD, MS; Perak, Amanda M. MD, MS, FAHA; Wei, Gina S. MD, MPH, FAHA; Gooding, Holly MD, MSc, Vice Chair; on behalf of the American Heart Association Council on Epidemiology and Prevention; Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council
